Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine

Institution (Facility)

Also Known As

Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine, Інститут патології крові та трансфузійної медицини НАМН України · Acronym: IPKTM

383

Publications

7.3K

Citations

Authors

Concepts

About

Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine is a facility institution in Lviv, Ukraine known for medicine, hematology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	16	1.7K
2	Health Sciences	8	8	1.4K
3	Engineering	2	2	61
4	Public Health	2	2	47
5	Diabetes	1	1	26

Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine

383

Publications

7.3K

Citations

Page 1

	Year	Citations
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, New England Journal of Medicine	2015	1.5K
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma Meletios Α. Dimopoulos, Andrew Spencer, Michael Attal, New England Journal of Medicine	2007	1.4K
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, The Lancet Oncology Hematological MalignancyOncologyRelapsed Multiple MyelomaHematologyMyeloid Neoplasia	2011	910
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial Sebastian Grosicki, Maryana Simonova, Ivan Špıčka, The Lancet Hematological MalignancyOnce-per-week SelinexorMedicineHematologyMyeloid Neoplasia	2020	310
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function Meletios Α. Dimopoulos, Adrían Alegre, Edward A. Stadtmauer, Cancer	2010	130
Randomized comparison of prophylaxis and on‐demand regimens with <scp>FEIBA NF</scp> in the treatment of haemophilia A and B with inhibitors Sandra Vallin Antunes, Srilatha Tangada, Oleksandra Stasyshyn, Haemophilia	2013	112
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors Tadashi Matsushita, Amy D. Shapiro, Aby Abraham, New England Journal of Medicine	2023	91
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos, Clinical Lymphoma Myeloma & Leukemia	2018	89
HLA-DR5 Antigen Gianmichele Peano Archives of Internal Medicine	1994	86
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A Johnny Mahlangu, Kazimierz Kuliczkowski, Faraizah Abdul Karim, Blood	2016	85

Page 1